Summary
BBS3012: Summary of all cases and Lectures
- Course
- Institution
All cases and lectures from the course BBS3012 from the minor Drug Intervention Track
[Show more]
Seller
Follow
ashleymaes
Reviews received
Content preview
BBS3012: FROM PHARMACOLOGICALMECHANISMS TO PRECISION MEDICINE
All cases and lectures
Biomedical Sciences: Minor Drug Intervention Track
1
,INHOUDSOPGAVE
Case 1: pharmacodynamics ............................................................................................................................ 5
Katzung, B. (2018). Basic & clinical pharmacology Chapter 2: Drug Receptors & Pharmacodynamics ............ 12
MACROMOLECULAR NATURE OF DRUG RECEPTORS ................................................................................... 12
(Case 2) ........................................................................................................................................................ 25
Case 3 .......................................................................................................................................................... 26
How is alcohol metabolized? ............................................................................................................................ 26
Interference (pharmacokinetics, pharmacodynamics) ................................................................................. 27
Estimate Peters’ blood alcohol level? ........................................................................................................... 27
ADME of paracetamol....................................................................................................................................... 28
WHat is the mechanism behind paracetamol toxicity? .................................................................................... 28
How can you treat this toxicity (NAC, gastric lavage)? ................................................................................. 30
Case 4: phenytoin interactions ..................................................................................................................... 32
What is phenytoin? Mode of action? Pharmacokinetic profile? ....................................................................... 32
Mechanism of action .................................................................................................................................... 32
Pharmacokinetic profile ................................................................................................................................ 32
What is plasma protein binding? What proteins are involved? ........................................................................ 33
What is the effect on the pharmaco-dynamics and -kinetics of the compounds? ............................................ 34
Explain the case (displacement of plasma proteins à how?, consequences?)................................................. 34
Would reduction of the dose solve this problem? If so, how?........................................................................... 35
Case 5: drug-drug interactions ...................................................................................................................... 36
Drug-drug interactions...................................................................................................................................... 36
Chapter 4, Drug-drug interactions ................................................................................................................ 36
Pharmacodynamic interactions .................................................................................................................... 37
Pharmacokinetic interactions ....................................................................................................................... 38
Mode of action of the mentioned drugs, pd, Toxic effects, concentrations and dose, PK, possible interactions?
.......................................................................................................................................................................... 40
Colchicine ...................................................................................................................................................... 40
Cyclosporine.................................................................................................................................................. 41
Mycophenolate mofetil ................................................................................................................................ 43
Prednisone .................................................................................................................................................... 44
Simvastatin ................................................................................................................................................... 46
Propofol ........................................................................................................................................................ 47
What is rhabdomyolysis? Drug-related causes? ............................................................................................... 49
Case 6 .......................................................................................................................................................... 52
PK and PD of codeine ........................................................................................................................................ 52
Impact of polymorphisms of CYP enzymes, prevalence of polymorphisms ....................................................... 53
What are CYP450 enzymes? Nomenclature? role in metabolism? ................................................................... 53
Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450 Inger Johansson, Magnus
Ingelman-Sundberg....................................................................................................................................... 56
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects
and functional diversity M Ingelman-Sundberg............................................................................................ 58
How do diet and other drugs interact with codeine? ........................................................................................ 58
2
, Information on opioids in general ..................................................................................................................... 58
Case 7 .......................................................................................................................................................... 60
What are the effects of age on drug response? ................................................................................................ 60
PK (body composition, metabolism) ............................................................................................................. 60
PD (sensitivity) .............................................................................................................................................. 61
What is the mode of action of sulphidimidine and chloramphenicol? .............................................................. 62
Sulphadimidine (Sulfamethazine) ................................................................................................................. 62
Chloramphenicol ........................................................................................................................................... 62
Ampicillin ...................................................................................................................................................... 63
What is the mode of action of methotrexate? .................................................................................................. 63
Side-effects (incl. nausea) ............................................................................................................................. 63
Interaction with folic acid ............................................................................................................................. 64
Case 8 .......................................................................................................................................................... 66
Lungcancer ........................................................................................................................................................ 66
Pathophysiology............................................................................................................................................ 66
types and stages ........................................................................................................................................... 67
What are EGFR and ALK? .................................................................................................................................. 69
How does screening help in choosing cancer treatment? ............................................................................ 69
What is a panel test? What panels are there? .................................................................................................. 69
What is RET? ................................................................................................................................................. 70
What is Alectinib? Why is it used in this case?.................................................................................................. 70
What is germline genetic screening? What is it used for? ................................................................................ 71
What kind of genes do you have to screen in order to predict efficacy and toxicity of drugs? ......................... 72
Look at results of genetic toxicity practical ....................................................................................................... 73
Lecture: pharmacodynamics 2 M. Blankesteijn ............................................................................................. 74
Lecture: pharmacokinetics 1 G. den Hartog .................................................................................................. 80
Quantifying events following an intravenous bolus .......................................................................................... 86
Volume of distribution and clearance........................................................................................................... 87
Quantifying Events Following an Oral Dose ...................................................................................................... 89
Lecture pharmacokinetics 2 G. den Hartog ................................................................................................... 91
Renal excretion ................................................................................................................................................. 91
Enzyme induction .............................................................................................................................................. 93
Multiple dosing ................................................................................................................................................. 95
Lecture: question hour ................................................................................................................................. 98
Lecture: pharmacoepigenetics A. Weseler .................................................................................................. 100
DNA modification: (de)methylation ................................................................................................................ 100
Histone modifications ..................................................................................................................................... 101
Non-coding (nc)-RNA’s .................................................................................................................................... 101
ADME genes .................................................................................................................................................... 101
Epigenetic effects of drugs .............................................................................................................................. 102
3
, Pharmaco-epigenetics à precision medicine ................................................................................................. 103
Take home messages ...................................................................................................................................... 104
Lecture: pharmacotherapy from cradle to grave A. Weseler ....................................................................... 105
What to take into account for the pharmacotherapy of patients of different age? ....................................... 108
Lecture: Gut microbiome and drug response D. Jonkers ............................................................................. 113
4
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller ashleymaes. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $12.33. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
72042 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now